Skip to main content
Premium Trial:

Request an Annual Quote

Dana-Farber Cancer Scientists to Use HistoRx's Biomarker Profiling Tech

NEW YORK (GenomeWeb News) – Researchers at the Dana-Farber/Harvard Cancer Center will use HistoRx’s Aqua biomarker profiling technology in cancer studies and cancer treatment research, the company said Thursday.
 
More than 900 researchers at DF/HCC will use the company’s PM-2000 tissue analysis tool, which was purchased by Brigham and Women’s Hospital for its pathology core facility in 2005.
 
The core facility is a service center that provides tissue-based tests and analysis for several institutions, including Brigham and Women’s Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Harvard School of Public Health, Children’s Hospital Boston, Beth Israel Deaconess Hospital, and Massachusetts General Hospital.
 
The company’s Aqua technology is used to measure biomarker concentration with subcellular resolution in order to understand the safety and effectiveness of new drugs and companion diagnostics.
 
The PM-2000 system is used to measure protein biomarkers in tissue and in tissue microarrays that are based on fluorescent immunohistochemical methods.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.